Viking Therapeutics Q2 net loss widens, misses expectations
Overview
Viking Therapeutics Q2 net loss of $65.6 mln misses analyst expectations
EPS for Q2 misses estimates due to higher R&D and admin expenses
Company maintains strong cash position of $808 mln to support clinical trials
Outlook
Company expects top-line results from VENTURE-Oral study in 2H25
Viking plans IND submission for DACRA program in 4Q25
Amylin program IND filing expected in Q4 2025
Result Drivers
PHASE 3 TRIALS - Initiation of Phase 3 VANQUISH trials for VK2735 in obesity and type 2 diabetes
PHASE 2 ENROLLMENT - Completion of enrollment for Phase 2 VENTURE-Oral Dosing trial
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Miss | -$0.58 | -$0.45 (19 Analysts) |
Q2 Net Income | Miss | -$65.56 mln | -$51.60 mln (16 Analysts) |
Q2 Income from Operations | Miss | -$74.57 mln | -$59.10 mln (15 Analysts) |
Q2 Operating Expenses |
| $74.57 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Viking Therapeutics Inc is $101.00, about 68.2% above its July 22 closing price of $32.10
Press Release: ID:nPn9SCNZpa
Related Articles
Coca Cola (KO) Q4 Earnings Preview: Look for the Upside in the AI Initiatives, not in the Revenue and the EPS
Coca-Cola (KO) enters its fourth-quarter 2025 earnings call tomorrow with significant momentum. However, a fundamental shift is occurring.
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion Tre
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
